Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant

Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata)

Brand names: Olumiant (2 mg and 4 mg tablets)

Baricitinib is an oral Janus kinase (JAK) inhibitor used in dermatology for moderate-to-severe atopic dermatitis and for severe alopecia areata in adults.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits JAK1 and JAK2, interrupting cytokine signalling that drives the inflammation underlying atopic dermatitis and alopecia areata.

Prescribing in practice

  • JAK inhibitors carry MHRA-highlighted risks of serious infection, venous thromboembolism, major cardiovascular events and malignancy, so use cautiously in those over 65, smokers, and patients with cardiovascular or thrombotic risk factors.
  • Screen for and exclude active and latent infection, including tuberculosis and viral hepatitis, before starting.
  • Ensure vaccinations are up to date and avoid live vaccines during treatment.

Monitoring

Monitor full blood count, lipids, liver function and for signs of infection or thromboembolism during treatment.

Counselling the patient

  • Report signs of infection, chest pain, breathlessness or leg swelling promptly.
  • Keep up to date with recommended vaccinations and avoid live vaccines while treated.
  • Attend for the blood tests arranged to monitor treatment.

Evidence & guidelines

NICE recommends baricitinib for moderate-to-severe atopic dermatitis and for severe alopecia areata within its authorised indications, subject to MHRA safety advice on JAK inhibitors.

Reference: NICE TA878 (2023); BRAVE-AA1/AA2 Trials (King et al, NEJM 2022); MHRA JAK Inhibitor Safety Review; BAD Atopic Eczema Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways